MedPath

Cytonics Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:2
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Not Applicable
1 (33.3%)

Evaluation of CYT-108, a Recombinant Protease Inhibitor, for Treatment of Mild to Moderate Primary Osteoarthritis of the Knee

Phase 1
Not yet recruiting
Conditions
Osteoarthritis
Osteoarthritis, Knee
First Posted Date
2024-02-16
Last Posted Date
2024-04-16
Lead Sponsor
Cytonics Corporation
Target Recruit Count
22
Registration Number
NCT06263270
Locations
🇦🇺

Emeritus Research, Camberwell, Victoria, Australia

Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers

Not Applicable
Conditions
Diabetic Foot Ulcer
First Posted Date
2014-08-06
Last Posted Date
2014-08-06
Lead Sponsor
Cytonics Corporation
Target Recruit Count
274
Registration Number
NCT02209662

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

Phase 1
Conditions
Osteoarthritis
Pain
First Posted Date
2014-08-06
Last Posted Date
2015-08-21
Lead Sponsor
Cytonics Corporation
Target Recruit Count
300
Registration Number
NCT02210468
Locations
🇺🇸

IRC Clinical, Townsend, Maryland, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath